ABSTRACT-Immune complexes in glomeruli are involved in development of diverse glomerulonephritis. The disposal process of glomerular immune complexes has been unclarified. The present studies were un dertaken to determine if thromboxane A2 (TXA2) is associated with the disposal of macromolecules in the glomeruli using mice injected with aggregated bovine serum albumin (a-BSA). A-BSA promptly accumu lated in the glomeruli, the level reaching a plateau at 6 hr after the injection of a-BSA, and then decreased by 48 hr. The production of glomerular TXA2, prostaglandin E2 (PGE2) and prostaglandin 12 concomitantly increased with the decrease of a-BSA in the glomeruli. TXA2 synthase inhibitors and TXA2 receptor an tagonists accelerated clearance of glomerular a-BSA without enhancing renal tissue blood flow. They did not affect a-BSA level in the plasma. In contrast, aminophylline, dopamine and mannitol significantly in creased renal tissue blood flow, but did not decrease glomerular a-BSA. TXA2 synthase inhibitors decreased TXA2 production in the glomeruli. TXA2 synthase inhibitors and TXA2 receptor antagonists did not influence the generation of PGE2. The TXA2 analogue U-46619 significantly increased the accumulation of a-BSA in the glomeruli. We propose that TXA2 interferes with the disposal process of aggregated protein in the glomeruli. We also postulate that interception of glomerular activity of TXA2 may be an effective inter vention for managing immune complex-mediated glomerulonephritis and glomerulosclerosis.
Much attention has been paid to the mesangium because of its involvement in the glomerular alterations of kidney diseases. The mesangial cells exist not only to support capillary vessels in the glomerulus but also act as phagocytic cells (1) . Cultured mesangial cells can engulf immune complexes (2) and colloidal gold particles (3) . The mesangial cells express thromboxane A2 (TXA2) receptors on their surface (4) , and TXA2 can contract cultured mesangial cells (5) as well as vascular smooth muscle (6) . Additionally, Singhal et al. reported that the TXA2 analogue U-46619 increased the endocytosis of immunoglobulin G immune complexes by cultured mes angial cells (7) . Thus, this revealed the ability of TXA2 to regulate the function of the mesangial cells via the surface receptor. Recently, Namba et al. cloned a cDNA for a mouse TXA2 receptor and demonstrated that TXA2 receptor mRNA was expressed in the mouse kidney (8) . TXA2-receptor cDNA for the rat was also isolated from the kidney (9) and TXA2-receptor protein was revealed in the rat glomeruli, including mesangial cells, by the im munofluorescence technique (10) .
Many investigators have reported that TXA2 produc tion is enhanced in diverse types of renal disease and ex perimental nephritis (11) (12) (13) . A TXA2 synthase inhibitor and a TXA2 receptor antagonist exerted an anti-nephritic effect on experimental nephritis in rats and a mouse lupus nephritic model, respectively (14) (15) (16) . We reported that DP-1904, a TXA2 synthase inhibitor, improved the clini cal manifestations, although the treatment with DP-1904 was started after the nephritis had been established (17) . Surprisingly, DP-1904-treated nephritic rats exhibited less deposition of rabbit immunoglobulin G in the glomeruli as compared with the control rats (17) .
Generally, TXA2 is inclined to have certain contrary action to prostaglandins (18) . Previously, we demon strated that prostaglandin E2 (PGE2) and prostaglandin 12 (PGI2) accelerated the clearance of aggregated bovine se rum albumin (a-BSA) in the glomeruli (19) . Such findings on the effect of PGE2 and the TXA2 synthase inhibitor led us to hypothesize that TXA2 interferes with the clearance of immune complexes in the nephritic glomeruli. To test this possibility, in this study, we performed experiments in mice injected with a-BSA. We investigated the effects of TXA2 synthase inhibitors, TXA2 receptor antagonists and a thromboxane analogue on the disposal process of aggregated protein in the glomeruli.
We found that TXA2 synthase inhibitors and TXA2 receptor antagonists facilitated the clearance of a-BSA and the TXA2 analogue retarded the clearance of a-BSA in the glomeruli. This is the first report indicating that TXA2 can disturb the glomerular disposal process of aggregated protein in in vivo experiments.
MATERIALS AND METHODS

Animals
Mail ICR strain mice, 4-weeks-old weighing approxi mately 25 g, were obtained from Nihon Clea (Tokyo) and housed in an air-conditioned room at 22 ± 2 C with a 12 hr light-dark cycle until used in the experiments. They had access to water and standard mouse chow ad libitum.
Drugs
Thromboxane synthase inhibitors were provided by the following companies: DP-1904
Co. (Nagano), and Y-19018 (2,4,6,2 tetramethyl-5'-(1-imidazolyl)-diphenyl hydroxy methan) and Y-20811 (sodium 4-(ahydroxy-5-(1-imid azolyl)-2-methylbenzyl)-3,5-dimethylbenzoate dihydrate) from Yoshitomi Pharmaceutical Co. (Osaka). TXA2 receptor antagonists, KT2-962 (sodium 3-(4-(4-chlorophenyl butylsulfonamido)butyl)-6-isopropylazulene-l-sulfonate) and ONO 3708 ((9,11), (11, 12) -dideoxa-9a,1 l a-dimethylmeth ano-11,12-methano-13,14-dihydro-13-aza-14-oxo-15-cyclo pentyl-16,17,18,19,20-pentanor-15-epi-thromboxane A2), were provided by Kotobuki Pharmaceutical Co. (Naga no) and Ono Pharmaceutical Co. (Osaka), respectively. Other drugs were purchased from the following com panies: aminophylline from Eisai Pharmaceutical Co. (Tokyo) and dopamine and mannitol from Wako Pure Chemical Industries Co. (Osaka). U-46619 (15S-hydroxy lla,9a-(epoxymethano)prosta-5Z,13E-dienoic acid) was purchased from Sigma Chemical (St. Louis, MO, USA). ONO 3708 was dissolved in saline at a concentration of 10 mg/ml. Mannitol was dissolved in saline to make a 25% solution. U-46619 was stocked in ethanol at a concentra tion of 350 pg/ml and used after an appropriate dilution with saline. Other drugs were dissolved in distilled water.
A-BSA A-BSA was prepared according to the previously reported procedure (19) . Briefly, crystallized BSA (Sei kagaku Co., Tokyo) was dissolved in saline at a concen tration of 300 mg/ml. The solution was alkalinized (pH 10) with 0.2 N NaOH and then heated at 701C for 20 min followed by further heating at 79C for 15 min. After cooling at room temperature, the solution was neutralized with 0.2 N HCl and centrifuged at 3,500 rpm for 30 min. The supernatant was stored in a freezer until use. Mice were injected with 120 mg/100 g body weight of a-BSA solution three times every 3 hr. The kidneys were isolated at various periods under ether anesthesia.
Measurement of a-BSA in the glomeruli
Staining of glomerular a-BSA was performed accord ing to the slightly modified method as described pre viously (19) . The kidneys were fixed in 10% buffered formalin and the tissues embedded in paraffin were then cut into 2 to 3-pm thick sections. Deparaffinized sections were treated with 0.05% protease (Type VIII, Sigma Chemical) solution for 3 min at room temperature; and after rinsing with phosphate-buffered saline, tissue per oxidase was blocked with 4.5% H2O2 solution. Sections were then incubated with affinity purified rabbit anti bovine serum albumin (Yagai Co., Yamagata) for 60 min, with biotinated goat anti-rabbit immunoglobulin G (Histofine; Nichirei Co., Tokyo) for 10 min, and with peroxidase-conjugated streptavidin for 5 min. A-BSA deposited in the glomeruli was visualized with 3,3'-di aminobenzidine tetrahydrochloride (Vector Institution, Burlingame, CA, USA). The total a-BSA positive area per glomerular cross section was morphometrically measured for 15 glomeruli per section by using an image analyzer (Toyobo V-1; Toyobo Co., Tokyo) and present ed as the mean positive area of a-BSA, namely pmt /glomerular cross section (GCS). Generally, the immuno histologically positive area in glomeruli has been scored as mild, moderate and severe. However, we have thought that scoring the positive area is not exactly quantitative because this measurement depends on a rough grading. The present procedure for quantitating the positive area provides digital data and eliminates subjectivity. There fore, we determined the positive area of a-BSA in the glomeruli by this method.
Measurement of a-BSA in plasma
The mice were administered each drug at 3 hr after the last injection of a-BSA. Blood was drawn by puncturing the retro-orbital venous with a capillary glass pipet at 3 hr after the drug treatment. The blood was transferred to a heparinized microtube and then centrifuged at 41C to obtain the plasma. The content of a-BSA in the plasma was determined by enzyme-linked immunosorbent assay (ELISA) using affinity purified rabbit anti-BSA serum (Yagai Co.), peroxidase-conjugated goat anti-rabbit im munoglobulin G (Cappel Laboratories, West Chester, PA, USA) and o-phenylenediamine (Sigma Chemical).
Measurement of TXA2, PGE2 and PGI2
Samples for TXA2, PGE2 and PGI2 were prepared by the modified method of Zoja et al. (20) . Briefly, the glomerular rich fraction was obtained by the sieving technique. The fraction was suspended in 2 ml of Krebs Ringer phosphate buffer. The suspension was incubated at 37C for 60 min and then centrifuged at 5,000 rpm for 5 min to obtain the supernatant as a sample for raidio immunoassay. Indomethacin (Wako Pure Chemicals) was added to the supernatant at the concentration of 10 pg/ml. The samples were stored at 80'C until the measurement. TXB2 was determined for TXA2 and 6 keto-prostaglandin Fla (PGFIa) for PGI2 because TXA2 and PGI2 are metabolized to TXB2 and 6-keto-PGFIa, respectively, in a very short time. TXB2, PGE2 and 6-keto-PGFIa were measured with commercial radio immunoassay kits (New England Nuclear, Boston, MA, USA) according to the manufacture's instructions. The glomeruli were lyophilized and then dissolved in 1 ml of 1 N NaOH. Protein content in the glomeruli was measured by the Bio-Rad protein assay (Bio-Rad Laboratories, Richmond, CA, USA).
Determination of renal tissue blood flow
Renal tissue blood flow was measured in accordance with the previously reported method (16) . Mice were in jected with 120 mg/100 g body weight of a-BSA. Drugs were administered at 1 hr after the injection of a-BSA. At 2 hr after a-BSA injection, renal tissue blood flow was measured twice by the hydrogen clearance method, with hydrogen gas generated by the electrolysis of body fluid (RBF-2; Biomedical Science Co., Ishikawa) (16).
Statistical analyses
The results obtained are expressed as the mean±S.E.M.
The data were analyzed by one-way anal ysis of variance (ANOVA) or the Kruskal-Wallis test. To determine the significance of differences among the groups, Tukey's test or Ryan's procedure was used. 
RESULTS
Kinetics of glomerular a-BSA and plasma a-BSA (Figs. 1 and 2) A-BSA in the glomeruli promptly accumulated within 3 hr after the injection of a-BSA. The higher level of glomerular a-BSA lasted until 12 hr, although the injec tion of a-BSA had been discontinued at 6 hr (193.7 tcm2 /GCS at 12 hr). Thereafter, glomerular a-BSA gradually decreased (68.0 pmt /GCS at 48 hr) (Fig. la) . There was little a-BSA in the non-treated mouse glomeruli (Fig. 2a) . A-BSA was located on the capillary wall and mesangial area (Fig. 2b ). Plasma a-BSA level consistently increased after the a-BSA injection, reaching a peak at 9 hr (3.14 mg/ml). At 48 hr, plasma a-BSA decreased to 10% of the peak level (Fig. lb) . These results indicate that there is a limited capacity to retain aggregated protein in the glomeruli and that the deposition of a-BSA may be de pendent on the plasma a-BSA level. We used the present procedure to determine the glomerular a-BSA in the fol lowing experiments. Kinetics of eicosanoid production of the glomeruli (Fig.  3) Conspicuous elevation of eicosanoid production was not observed until 9 hr after the injection of a-BSA. At 12 hr, both TXB2 level and PGE2 level augmented 1.5 to 2.5-fold, respectively (Fig. 3) . TXB2 generation peaked at 36 hr (Fig. 3a) . PGE2 generation increased twofold even at 36 hr and then returned to the basal level by 48 hr (Fig.  3b) . The kinetics of 6-keto PGF1a was similar to that of TXB2 (data not shown). These findings suggest that ei cosanoid is associated with the clearance of a-BSA in the glomeruli. To elucidate the role of TXA2 regarding the clearance of a-BSA in the glomeruli, we administered TXA2 syn thase inhibitors or TXA2 receptor antagonists to the a-BSA-loaded mice. In the control mice 109.4 ,um2/GCS of a-BSA was present at 9 hr after the first injection of a-BSA. The administration of DP-1904 significantly diminished the area of a-BSA in the glomeruli in a dose dependent manner (85.3 pmt/GCS at 10 mg/kg and 64.0 ,um2/GCS at 20 mg/kg, respectively) (Fig. 4a) . Further more, we observed around 50% less a-BSA in the glomeruli of the mice treated with OKY-046 or Y-2081 1, a TXA2 synthase inhibitor, when compared with the con trol group (Fig. 4b) . TXA2 receptor antagonists, KT 2 962 and ONO 3708, diminished glomerular a-BSA dose dependently, as did TXA2 synthase inhibitors (Fig. 2: c  and d) . KT 2-962 at 45 mg/kg and ONO 3708 at 100 and 200 mg/kg resulted in 49%, 49% and 58% decrease of glomerular a-BSA, respectively, as compared with the control mice (Fig. 5) . On the other hand, plasma a-BSA level and the amount of a-BSA excreted in urine were not affected by the treatment of these drugs (data not shown). Both TXA2 synthase inhibitors and TXA2 receptor antagonists accelerated the clearance of a-BSA in the glomeruli, strongly suggesting that TXA2 interferes with the disposal process of a-BSA in the glomeruli. Effect of TXA2 synthase inhibitor and TXA2 receptor an tagonist on the generation of eicosanoid in the glomeruli (Fig. 6) DP-1904 at 20 mg/kg and Y-20811 at 4 mg/kg sig nificantly diminished the glomerular production of TXA2 by around 60% of the control mice (Fig. 6a) . TXA2 receptor antagonists, however, did not exhibit any reduction of the glomerular generation of TXA2 (Fig. 6a) . Neither TXA2 synthase inhibitors nor TXA2 receptor an tagonists exerted any effects on the production of PGE2 (Fig. 6b) . These results show that the present dose of TXA2 synthase inhibitors is sufficient to diminish the generation of TXA2 in the a-BSA-loaded glomeruli without any influence on the generation of PGE2 and that the present dose of TXA2 receptor antagonists dose not
give rise to any changes in the generation of PGE2 and TXAZ.
Effects of drugs which increase renal blood flow on clearance of glomerular a-BSA (Fig. 7 ) Aminophylline, dopamine and mannitol failed to accelerate the decrease of glomerular a-BSA (Fig. 7a) , although they significantly increased renal tissue blood flow (64%, 63% and 63% increase vs control, respective ly) (Fig. 7b) . On the other hand, the TXA2 synthase in hibitor and the TXA2 receptor antagonist did not increase renal tissue blood flow in a-BSA-loaded mice (data not shown). Renal blood flow does not seem to be related to the clearance of a-BSA in the glomeruli.
A TXA2 analogue U-46619 deters glomerular disposal of a-BSA (Fig. 8) To further elucidate the role of TXA2, U-46619 was injected into the mice at 3 hr after the last injection of a-BSA when the level of a-BSA in the circulation had already began to fall. The mice treated with U-46619 showed more accumulation of a-BSA in the glomeruli, dose-dependently, than the control mice (10% increase at 3.5 ng/mouse and 35% increase at 35 ng/mouse, respec tively) (Fig. 8a) . U-46619 had no effect on the plasma a-BSA level at any dosage (Fig. 8b) . This result comple ments the findings obtained from the experiments using TXA2 synthase inhibitors and TXA2 receptor antago nists, suggesting that TXA2 disturbs the clearance of a-BSA in the glomeruli. 
DISCUSSION
In the present experiments, to elucidate the involve ment of TXA2 in the clearance of aggregated protein in the glomeruli, we used several kinds of TXA2 synthase inhibitors and TXA2 receptor antagonists. We demon strated significantly decreased glomerular a-BSA in the mice treated with the TXA2 synthase inhibitors or the TXA2 receptor antagonists as compared with the control mice. We previously reported that the TXA2 synthase in hibitors increased glomerular production of PGE2 and PGI2 in contrast with decreased TXA2 production in nephritic rats (16) and that PGE2 and PGI2 significantly accelerated the decrease of a-BSA in the glomeruli (19) . Therefore, it is possible that the TXA2 synthase inhibitors may accelerate the process of a-BSA in the glomeruli via the effect of PGE2 and PGI2. We determined the TXA2 and PGE2 level generated by a-BSA-loaded glomeruli treated with the TXA2 synthase inhibitors. While the TXA2 synthase inhibitors diminished the production of TXA2, the TXA2 synthase inhibitors failed to enhance the production of PGE2. Because the production of PGE2 in the glomeruli was augmented 2.5-fold by loading a-BSA, the increase in PGE2 induced by the TXA2 synthase inhibitor may have been masked. Higo and Karasawa indicated that a TXA2 synthase inhibitor did not increase the production of PGI2 in the dissected segment of guinea pig thoracic aorta with intact endothelium or injured endothelium (21). They observed an enhanced level of PGI2 in the plasma obtained from endothelium-injured animals, not from intact-endothelium animals, treated with the TXA2 synthase inhibitor. Thus, it is unlikely that PGE2 and PGI2 affected the accelerating effect of the TXA2 synthase inhibitor on the disposal process of ag gregated protein in the glomeruli, although we did not measure the PGI2 generation in a-BSA-loaded glomeruli from the mice treated with the TXA2 synthase inhibitor. Additionally, PGF2a does not seem to be associated with the effect of the TXA2 synthase inhibitors because PGF2a did not exert any effect on glomerular clearance of aggregated protein in the previous experiments (19) .
Mesangial cell contraction is linked to intraglomerular physiological changes (22, 23) , and PGE2 and TXA2 modu late the contractility of the mesangial cells in vitro (5) . Moreover, TXA2 receptor antagonists and TXA2 synthase inhibitors are considered to cause the increase of renal blood flow. Lee and Vernier observed the localization of aggregated human albumin (a-HA) in the glomeruli by the immunoelectron microscopy technique (24) . The a HA rapidly entered the mesangial area, and part of it was engulfed by mesangial cells. The rest of the a-HA in the mesangial area was transported to the juxtaglomerular region via mesangial channels and into the interstitial space. Therefore, although they did not describe the effect of the blood flow or fluid flow on the mesangial drainage, it is considered that a-BSA in the glomeruli is dispersed through the mesangial channel by the increased blood flow caused by the current agents and that TXA2 inter feres with the function of mesangial drainage. However, neither the TXA2 synthase inhibitors nor the TXA2 receptor antagonists augmented renal tissue blood flow. On the contrary, while aminophylline, dopamine and mannitol significantly enhanced the renal tissue blood flow, they failed to accelerate the clearance of glomerular a-BSA. Accordingly, the present results suggest that the TXA2 synthase inhibitors and the TXA2 receptor antago nists promote the processing of a-BSA by the mesangial cells and/or other cells. We do not, however, exclude the possibility that the present data do not reflect the blood flow in the glomeruli because the present data showed the renal tissue blood flow, not glomerular blood flow. Fur ther investigations are required to elucidate in this aspect. In the present experiments, the kinetics of glomerular a-BSA was similar to that in the circulation, and ac cumulation of a-BSA was accompanied by increased PGE2 and TXA2 generation in the glomeruli. However, the prominently increased production of PGE2 and TXA2 was observed after 12 hr in a-BSA-loaded glomeruli. On the other hand, the large quantities of a BSA was retained in the glomeruli until 12 hr and then gradually decreased. These findings seem to conflict with the present hypothesis that TXA2 inhibits the disposal process of aggregated protein in the glomeruli; namely, while a-BSA had been accumulating into the glomeruli, the glomerular TXA2 generation was at basal level and when glomerular a-BSA decreased, the TXA2 generation increased.
Prostaglandins are biosynthesized from arachidonic acid by cyclooxygenase (Cox), a hemo protein. Two forms of Cox have been identified (25, 26) . The constitutive isoform (Coxl) is present in tissues to maintain the normal physiological process. The in ducible isoform (Cox2) is expressed in many cells at the site of inflammation and accounts for the release of large quantities of prostaglandins in inflammation (27, 28) . Cultured mesangial cells express Cox2 mRNA in a few hours following proinflammatory cytokine, interleukin 1~, stimulation. The detectable generation of PGE2 fol lows 4-6 hr after the Cox2 mRNA expression (29) . A time lag for increasing TXA2 may result from the time required for Cox2 expression in a-BSA-loaded glomeruli. Therefore, TXA2 may not be associated with this increase of deposition of a-BSA in the glomeruli during 12 hr after the injection.
In in vitro experiments, TXA2 enhanced the uptake of macromolecules by cultured mesangial cells (7, 30) . Therefore, it can be considered that the treatment of a TXA2 receptor antagonist or a TXA2 synthase inhibitor would inevitably lead to the prolonged the clearance of a-BSA from the circulation. Inversely, if a-BSA is ac cumulated in the mesangial area by the treatment of the TXA2 receptor antagonists or the TXA2 synthase inhibi tors, and then drained from mesangial area, a-BSA in the circulation should have rapidly decreased. However, the level of a-BSA in the plasma was never affected by the treatment of the TXA2 receptor antagonists or the TXA2 synthase inhibitors. In addition, we determined the level of a-BSA in the glomeruli and plasma after the injection of U-46619, a TXA2 analogue, into the a-BSA-charged mice because U-46619 was demonstrated to bind to TXA2 receptors in glomerular membrane (31) . The mice treated with U-46619 showed more a-BSA in the glomeruli than the control mice, yet the plasma level of a-BSA was similar to that in the control mice, suggesting that TXA2 interferes with the clearance of aggregated protein in the glomeruli.
Immune complex deposition in the glomeruli is charac teristic of immunologically-mediated glomerulonephritis. Furthermore, the elicitation of polymorphonuclear leuko cytes and monocytes in the glomeruli accompanied by proliferation of resident cells and expansion of the mesangial matrix is observed in glomerulonephritis. Retardation of disposal of immune complexes in the glomeruli could prolong renal disease, and excess production and accumulation of matrix or aggregated protein could lead to sclerosis in the glomeruli. Dysfunc tion and sclerosis of the glomeruli must be prevented. Focal segmental glomerulosclerosis is the predominant glomerular lesion in heroin addicts. Singhal et al. demon strated that morphine inhibited uptake of the im munoglobulin G complex by cultured mesangial cells and macrophages in vitro, and morphine-treated rats showed the enhanced accumulation of 125I-anti human im munoglobulin G into glomeruli (32) . They suggested that the increased accumulation of phlogogenic macromolec ules into the mesangium may alter both the quantity and quality of the mesangial matrix and may consequently cause glomerulosclerosis (32) . Therefore, acceleration of glomerular disposal of altered mesangial matrix and im mune complexes by drug treatment is likely to halt the progression of glomerulonephritis and suppress the alter ations leading to glomerulosclerosis. In addition to the experiments using the isolated glomeruli, investigations are required to elucidate the disposal process of aggre gated protein in the nephritic glomeruli.
